C2N Diagnostics

10/14/2025

On October 15th, The Atlantic and WashU Olin Business School will convene a free half day Summit in St. Louis to explore how medical breakthroughs – especially in complex fields like neurological disease – can move from discovery to real-world impact at scale. Dr. Joel Braunstein, CEO of C2N Diagnostics, will speak on a panel addressing “Beyond the Lab: Making Breakthroughs Reach People.”

Led by AtlanticLIVE contributor, Jeanne Meserve, Dr. Braunstein and other panelists will address how promising scientific discoveries emerge from academic labs and how science becomes system change and what it takes to navigate the complex path from research to commercialization, implementation, and broad adoption.

Register to attend virtually or in person - https://www.theatlantic.com/live/the-business-of-health/

10/06/2025

WEBINAR ALERT
Advances in research have identified hallmarks of Alzheimer’s disease through blood biomarker tests (BBM). Compared to traditional imaging methods, BBMs are more accessible, cost-effective, and is a very promising tool for advancing diagnosis among individuals with cognitive concerns.

The implementation of BBMs with digital cognitive assessments (DCA) in clinical research applications can bring several advantages, such as identifying people at risk of developing conditions such as Alzheimer’s disease as well as facilitating disease monitoring.

This expert-led webinar will discuss research challenges, and give you the opportunity to ask the experts in our live Q&A .

Learn how the strategic integration of BBMs and DCAs can improve detection, enhance precise monitoring, and potentially, more effective therapeutic intervention.

In this 60-minute webinar on Oct. 29, you will:
• Uncover the critical limitations of conventional assessment methods like CSF/PET and paper-and-pencil tests in modern neurological research.

• Learn how combining BBMs and DCAs can provide a multi-dimensional view of brain health.

• Identify concrete strategies to improve participant screening, enhance recruitment, and implement more sensitive monitoring of disease progression and treatment effects.

• Gain practical knowledge on implementation, from tool selection and data integration to navigating the challenges of standardization and validation.

• See how richer, integrated datasets that connect biological signals to clinical manifestations can lead to more compelling evidence for regulators.

Speakers:
Martina De Lillo, PhD, Clinical Scientist
Francesca Cormack, PhD, Chief Scientist
Joel B. Braunstein, MD, MBA, Co-Founder and CEO, C2N Diagnostics
Christoffer Hatlestad-Hall, PhD, Postdoctoral Researcher

238abbf4-70e9-4c4b-b336-7b09df1d6302@9965b91a-cdae-477c-8430-54e57a5778e6" rel="ugc" target="_blank">https://events.teams.microsoft.com/event/238abbf4-70e9-4c4b-b336-7b09df1d6302@9965b91a-cdae-477c-8430-54e57a5778e6

10/03/2025

St. Louis magazine in C2N’s hometown names CEO Dr. Joel Braunstein to its Business 500 List👏

It’s “a guide to some of the metro area’s most influential, impactful, and innovative leaders.”

Click here to read a recap of Dr. Braunstein and C2N’s accomplishments www.stlmag.com/business/st-louis-business-500-health-care/

10/01/2025

🚨C2N Submits U.S. FDA Regulatory Filing for Its Alzheimer’s Disease Blood Test

Company Seeks to Establish a First in the Field of Medicine with Pioneering Diagnostic Algorithm Test Using High Resolution Mass Spectrometry

C2N believes this is a first for the entire field of medicine: the first multi-analyte algorithmic blood test using high-resolution mass spectrometry (HRMS) submitted for FDA review, for use in the assessment of Alzheimer’s disease pathology. HRMS is a powerful technology that represents a significant advancement in the field of clinical laboratory diagnostics, enabling the detection of circulating proteins from blood with high analytical sensitivity and specificity.

https://c2n.com/news-releases/c2n-submits-us-fda-regulatory-filing-for-its-alzheimers-disease-blood-test

10/01/2025

C2N CEO Dr. Joel Braunstein will be speaking at the Splash Clinical Summit, which is designed to “spark collaboration, share insights, and tackle some of the toughest challenges in clinical trials today.”

Dr. Braunstein will be discussing the role and value of blood biomarkers in Alzheimer’s disease research.

Further information👉https://www.splashclinical.com/the-second-annual-splash-clinical-summit-in-raleigh/

Learn more about Dr. Braunstein👉 https://c2n.com/our-team

Full details about C2N’s role developing and commercializing novel diagnostics for Alzheimer’s disease and related forms of neurodegeneration to improve treatment decisions and patients’ lives 👉www.C2N.com

09/29/2025

We’re still excited about the reaction to the news that we’re relocating our headquarters and expanding our federally regulated CAP accredited-CLIA certified lab operation to 4140 Forest Park Ave. at Catalyst, Powered by WashU, in the Cortex Innovation Community in St. Louis.

Here's a news story from KMOX News in St. Louis. www.audacy.com/kmox/news/local/cortex-lab-100-previously-proposed-projects-revived

“Today there’s not a single available vacant square foot of lab space in Cortex,” Sam Fiorello, President and CEO of the district, tells KMOX. The final spot was claimed by Varro Life Sciences, leaving Cortex at full capacity.

09/26/2025

Get to know our CEO Dr. Joel Braunstein as he’s a guest on Literal Humans, hosted by Paul David!🎧

Dr. Braunstein explains the Precivity™ tests, which are innovative new blood tests intended for use in patients 50 and older with signs or symptoms of mild cognitive impairment or dementia. These tests aid healthcare providers in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease, and inform medical management and treatment decisions.

Added bonus: He shares personal insights, quickfire takes on tech innovation, and the philosophies that keep him grounded.

https://literalhumans.com/podcast/transforming-alzheimers-disease-diagnosis-through-blood-tests-with-dr-joel-braunstein-from-c2n-diagnostics/

In this episode of Tech Can’t Save Us, Paul speaks to Dr. Joel Braunstein, CEO and Co-founder of C2N Diagnostics.

09/25/2025

New Research Reinforces C2N’s PrecivityAD2™ Blood Test as a Highly Accurate Tool to Detect Brain Amyloid Pathology in Symptomatic Patients

Nature: npj Dementia Publishes Findings About the PrecivityAD2™ Test, Which Aids Healthcare Professionals in Diagnosing Alzheimer’s Disease

The research states that the PrecivityAD2™ blood test demonstrated 91% accuracy, 90% sensitivity and 92% specificity using the CLIA-established cutoff versus amyloid PET imaging, which healthcare professionals have traditionally had to rely on to make an Alzheimer’s disease diagnosis. C2N says the outcome confirms the test’s “repeatable, reliable and robust” performance.

The research appears in npj Dementia, which is part of the Nature Portfolio.



https://c2n.com/news-releases/new-research-reinforces-c2ns-precivityad2-blood-test-as-a-highly-accurate-tool-to-detect-brain-amyloid-pathology-in-symptomatic-patientsnbsp

09/03/2025

C2N Diagnostics is proud to announce that its early achievements while based in St. Louis are allowing it to triple the size of its operations in its hometown.

C2N expresses its thanks to the following for their support throughout the process: Governor Mike Kehoe; Mayor Cara Spencer, City of St. Louis; Alderman Michael Browning, City of St. Louis; Cortex Innovation Community; Cushman & Wakefield; Greater St. Louis, Inc.; Missouri Department of Economic Development; St. Louis Development Corporation; and Washington University in St. Louis.



https://c2n.com/news-releases/dynamic-growth-leads-c2n-diagnostics-to-expand-st-louis-headquarters-to-meet-global-need-for-answers-to-alzheimers-disease-nbsp

08/25/2025

Clinicians worried about early-onset Alzheimer’s disease in patients with cognitive concerns between the ages of 50 and 55 years can now prescribe the PrecivityAD2™ blood test to aid in the diagnosis of the neurological disorder for that expanded population.

The test helps healthcare professionals in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease, and helps inform medical management and treatment decisions.

Please see here for more details on this important news! https://precivityad.com/news/c2n-diagnostics-expands-the-precivityad2-alzheimers-disease-blood-test-intended-use-to-patients-50-years-and-older

Lower Age Limit Addresses Increasing Calls from Clinicians Seeking Access to the PrecivityAD2™ Test for Patients With Earlier Onset of Cognitive Symptoms; Test Provides Potential to Inform Earlier Intervention   ST. LOUIS — Aug. 25, 2025 — Clinicians worried about early-onset Alzheimer

08/07/2025

C2N Diagnostics is proud to be a sponsor of the Alzheimer Europe Anti-Stigma Award, which recognizes an outstanding initiative aimed at combating stigma and promoting a positive image of dementia and people living with dementia.

It’s open to artists who are using photography or painting to address stigma and convey a positive image of dementia and people living with dementia.

The deadline is soon: Sept. 1
https://bit.ly/AEAntiStigmaAward

See last year’s top awardee at https://www.alzheimer-europe.org/our-work/anti-stigma-award/anti-stigma-initiatives/documentary-film-alzheimer-mit-56-das?language_content_entity=en

Photo is of winners of the Anti-Stigma Award 2024 (left to right): Magnus Renggli, Ofelya Kamavosyan, Andreas Kreimaier

08/04/2025

C2N Diagnostics is always proud to acknowledge generous support from the Alzheimer's Drug Discovery Foundation.

Pharmaceutical Executive interviewed ADDF’s Chief Financial Officer Karen B. Harris and she provided further insights into how ADDF views C2N and its PrecivityAD™ line of blood tests that help healthcare providers diagnose Alzheimer’s disease.

Click here to read the article: www.pharmexec.com/view/fight-alzheimer-research-funding

The ADDF’s CFO discusses the areas that foundation is raising money for and how its reacting to the current economic environment.